The glucorcorticoid receptor is increased in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells, and its nuclear translocation counteracts c-myc expression

Steroids

Volumn 72, Issue 5, 2007, Pages 415-421

  Yan, Mingshan ^a   Kuang, Xianghong ^a   Scofield, Virginia L ^a   Shen, Jianjun ^a   Lynn, William S ^a   Wong, Paul K Y ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Ataxia telangiectasia mutated; C myc; Glucocorticoid; Glucocorticoid receptor; Thymic lymphoma; Thymocyte

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MIFEPRISTONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ATM PROTEIN; CELL CYCLE PROTEIN; DNA; DNA BINDING PROTEIN; HORMONE ANTAGONIST; MYC PROTEIN; PROTEIN SERINE THREONINE KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; GENE EXPRESSION; HORMONE BLOOD LEVEL; LEUKEMIA; LYMPHOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; THYMOCYTE; THYMUS LYMPHOMA; TUMOR CELL CULTURE; ACTIVE TRANSPORT; ANIMAL; BIOSYNTHESIS; CELL NUCLEUS; COMPARATIVE STUDY; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA; METABOLISM; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION; THYMUS; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA; MUS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL NUCLEUS; DEXAMETHASONE; DNA; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; HORMONE ANTAGONISTS; LYMPHOMA; MICE; MICE, KNOCKOUT; MIFEPRISTONE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; THYMUS GLAND; TUMOR SUPPRESSOR PROTEINS;

EID: 34247174790     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2007.02.004     Document Type: Article

References (39)

1. Lavin M.F. Radiosensitivity and oxidative signalling in ataxia telangiectasia: an update. Radiother Oncol 47 (1998) 113-123
2. Barlow C., Hirotsune S., Paylor R., Liyanage M., Eckhaus M., Collins F., et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86 (1996) 159-171
3. Xu Y., Ashley T., Brainerd E.E., Bronson R.T., Meyn M.S., and Baltimore D. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev 10 (1996) 2411-2422
4. Taylor A.M., Metcalfe J.A., Thick J., and Mak Y.F. Leukemia and lymphoma in ataxia telangiectasia. Blood 87 (1996) 423-438
5. Liyanage M., Weaver Z., Barlow C., Coleman A., Pankratz D.G., Anderson S., et al. Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice. Blood 96 (2000) 1940-1946
6. Yan M., Qiang W., Liu N., Shen J., Lynn W.S., and Wong P.K. The ataxia-telangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes. Faseb J 15 (2001) 1132-1138
7. Watson D.K., Reddy E.P., Duesberg P.H., and Papas T.S. Nucleotide sequence analysis of the chicken c-myc gene reveals homologous and unique coding regions by comparison with the transforming gene of avian myelocytomatosis virus MC29, delta gag-myc. Proc Natl Acad Sci USA 80 (1983) 2146-2150
8. Hayflick J., Seeburg P.H., Ohlsson R., Pfeifer-Ohlsson S., Watson D., Papas T., et al. Nucleotide sequence of two overlapping myc-related genes in avian carcinoma virus OK10 and their relation to the myc genes of other viruses and the cell. Proc Natl Acad Sci USA 82 (1985) 2718-2722
9. Nesbit C.E., Tersak J.M., and Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 18 (1999) 3004-3016
10. Dudley J.P., Mertz J.A., Rajan L., Lozano M., and Broussard D.R. What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas. Leukemia 16 (2002) 1086-1098
11. Felsher D.W., and Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4 (1999) 199-207
12. Cole M.D., and McMahon S.B. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 18 (1999) 2916-2924
13. Lindstrom M.S., and Wiman K.G. Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts. Oncogene 22 (2003) 4993-5005
14. Davis A.C., Wims M., Spotts G.D., Hann S.R., and Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7 (1993) 671-682
15. Douglas N.C., Jacobs H., Bothwell A.L., and Hayday A.C. Defining the specific physiological requirements for c-Myc in T cell development. Nat Immunol 2 (2001) 307-315
16. Ashwell J.D., Lu F.W., and Vacchio M.S. Glucocorticoids in T cell development and function*. Annu Rev Immunol 18 (2000) 309-345
17. Bledsoe R.K., Montana V.G., Stanley T.B., Delves C.J., Apolito C.J., McKee D.D., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110 (2002) 93-105
18. Schaaf M.J., and Cidlowski J.A. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 83 (2002) 37-48
19. Jondal M., Pazirandeh A., and Okret S. Different roles for glucocorticoids in thymocyte homeostasis?. Trends Immunol 25 (2004) 595-600
20. Kanelakis K.C., and Pratt W.B. Regulation of glucocorticoid receptor ligand-binding activity by the hsp90/hsp70-based chaperone machinery. Methods Enzymol 364 (2003) 159-173
21. Kino T., Souvatzoglou E., De Martino M.U., Tsopanomihalu M., Wan Y., and Chrousos G.P. Protein 14-3-3sigma interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway. J Biol Chem 278 (2003) 25651-25656
22. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., and Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 97 (2000) 3919-3924
23. Wang W., Wykrzykowska J., Johnson T., Sen R., and Sen J. A NF-kappa B/c-myc-dependent survival pathway is targeted by corticosteroids in immature thymocytes. J Immunol 162 (1999) 314-322
24. Wu M., Arsura M., Bellas R.E., FitzGerald M.J., Lee H., Schauer S.L., et al. Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol 16 (1996) 5015-5025
25. Liao M.J., Yin C., Barlow C., Wynshaw-Boris A., and van Dyke T. Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction. Mol Cell Biol 19 (1999) 3095-3102
26. Kuang X., Yan M., Liu N., Scofield V.L., Qiang W., Cahill J., et al. Control of Atm-/- thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone. Cancer Chemother Pharmacol 55 (2005) 203-212
27. Gibson U.E., Heid C.A., and Williams P.M. A novel method for real time quantitative RT-PCR. Genome Res 6 (1996) 995-1001
28. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
29. Yan M., Zhu C., Liu N., Jiang Y., Scofield V.L., Riggs P.K., et al. ATM controls c-Myc and DNA synthesis during postnatal thymocyte development through regulation of redox state. Free Radic Biol Med 41 (2006) 640-648
30. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297 (2002) 102-104
31. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431 (2004) 1112-1117
32. Beck C.A., Estes P.A., Bona B.J., Muro-Cacho C.A., Nordeen S.K., and Edwards D.P. The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors. Endocrinology 133 (1993) 728-740
33. Yan M., Kuang X., Qiang W., Shen J., Claypool K., Lynn W.S., et al. Prevention of thymic lymphoma development in Atm-/- mice by dexamethasone. Cancer Res 62 (2002) 5153-5157
34. Benassi B., Fanciulli M., Fiorentino F., Porrello A., Chiorino G., Loda M., et al. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 21 (2006) 509-519
35. Liu N., Stoica G., Yan M., Scofield V.L., Qiang W., Lynn W.S., et al. ATM deficiency induces oxidative stress and endoplasmic reticulum stress in astrocytes. Lab Invest 85 (2005) 1471-1480
36. Purton J.F., Monk J.A., Liddicoat D.R., Kyparissoudis K., Sakkal S., Richardson S.J., et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol 173 (2004) 3816-3824
37. Zhou F., Medh R.D., and Thompson E.B. Glucocorticoid mediated transcriptional repression of c-myc in apoptotic human leukemic CEM cells. J Steroid Biochem Mol Biol 73 (2000) 195-202
38. Medh R.D., Wang A., Zhou F., and Thompson E.B. Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells. Oncogene 20 (2001) 4629-4639
39. Cho S., Kagan B.L., Blackford Jr. J.A., Szapary D., and Simons Jr. S.S. Glucocorticoid receptor ligand binding domain is sufficient for the modulation of glucocorticoid induction properties by homologous receptors, coactivator transcription intermediary factor 2, and Ubc9. Mol Endocrinol 19 (2005) 290-311